Analyst Expectations For Hims & Hers Health's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Hims & Hers Health (NYSE:HIMS) over the past three months, with a notable increase in the average 12-month price target from $16.81 to $22.11. The company has shown strong financial performance, including a 45.81% revenue growth rate and a net margin of 4.0%.
August 06, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed ratings for Hims & Hers Health, with a significant increase in the average 12-month price target to $22.11. The company has demonstrated strong financial performance, including a 45.81% revenue growth rate and a net margin of 4.0%.
The increase in the average 12-month price target and strong financial performance metrics such as revenue growth and net margin are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100